# Immune Profiling During Ocrelizumab Treatment in Multiple Sclerosis

> **NCT03138525** · — · COMPLETED · sponsor: **Brigham and Women's Hospital** · enrollment: 161 (actual)

## Conditions studied

- Multiple Sclerosis
- Healthy

## Interventions

- **OTHER:** Blood sampling (MS)
- **OTHER:** Blood sampling (controls)

## Key facts

- **NCT ID:** NCT03138525
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-20
- **Primary completion:** 2019-12-20
- **Final completion:** 2019-12-20
- **Target enrollment:** 161 (ACTUAL)
- **Last updated:** 2021-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03138525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03138525, "Immune Profiling During Ocrelizumab Treatment in Multiple Sclerosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03138525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*